ArticleJournal of biomedical optics2012
Comparison of red-shifted firefly luciferase Ppy RE9 and conventional Luc2 as bioluminescence imaging reporter genes for in vivo imaging of stem cells.
Article in Journal of biomedical optics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Luciferase-induced immune activation prevents orthotopic K7M2luc osteosarcoma establishment in BALB/c mice.Radiology and oncology · 2026Article
- A multiplex hextuple luciferase assay for advancing cellular signaling analysis in plant cells.Plant communications · 2026Article
- OPTRACE: Optical Imaging-Guided Transplantation and Tracking of Cells in the Mouse Brain.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- BioluminescentFrontiers in cellular and infection microbiology · 2026Article
- Development and validation of Mayaro virus with luciferase reporter genes as a tool for antiviral assays.Heliyon · 2024Article
- A dual-luciferase bioluminescence system for the assessment of cellular therapies.Molecular therapy. Oncology · 2024Article
- Development of two mouse strains conditionally expressing bright luciferases with distinct emission spectra as new tools for in vivo imaging.Lab animal · 2023Article
- Comparison of Bioluminescent Substrates in Natural Infection Models of Neglected Parasitic Diseases.International journal of molecular sciences · 2022Article
- A Luciferase Mutant with Improved Brightness and Stability for Whole-Cell Bioluminescent Biosensors and In Vitro Biosensing.Biosensors · 2022Article
- Characterization and comparison of human glioblastoma models.BMC cancer · 2022Article
- A higher spectral range of beetle bioluminescence with infraluciferin.Frontiers in bioengineering and biotechnology · 2022Article
- Methionyl-tRNA synthetase inhibitor has potent in vivo activity in a novel Giardia lamblia luciferase murine infection model.The Journal of antimicrobial chemotherapy · 2020Article
- Examining multiple cellular pathways at once using multiplex hextuple luciferase assaying.Nature communications · 2019Article
- Optimizing live-animal bioluminescence imaging prediction of tumor burden in human prostate cancer xenograft models in SCID-NSG mice.The Prostate · 2019Article
- QuantitativeNeurophotonics · 2019Article
- New imaging probes to track cell fate: reporter genes in stem cell research.Cellular and molecular life sciences : CMLS · 2017Review
- Red-emitting chimeric firefly luciferase for in vivo imaging in low ATP cellular environments.Analytical biochemistry · 2017Article
- Imaging Adenosine Triphosphate (ATP).The Biological bulletin · 2016Review
- A bright cyan-excitable orange fluorescent protein facilitates dual-emission microscopy and enhances bioluminescence imaging in vivo.Nature biotechnology · 2016Article
- Co-Registration of Bioluminescence Tomography, Computed Tomography, and Magnetic Resonance Imaging for MultimodalTomography (Ann Arbor, Mich.) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
One critical issue for noninvasive imaging of transplanted bioluminescent cells is the large amount of light absorption in tissue when emission wavelengths below 600 nm are used. Luciferase with a red-shifted spectrum can potentially bypass this limitation. We assessed and compared a mutant of firefly luciferase (Ppy RE9, PRE9) against the yellow luciferase luc2 gene for use in cell transplantation studies. C17.2 neural stem cells expressing PRE9-Venus and luc2-Venus were sorted by flow cytometry and assessed for bioluminescence in vitro in culture and in vivo after transplantation into the brain of immunodeficient Rag2-/- mice. We found that the luminescence from PRE9 was stable, with a peak emission at 620 nm, shifted to the red compared to that of luc2. The emission peak for PRE9 was pH-independent, in contrast to luc2, and much less affected by tissue absorbance compared to that of luc2. However, the total emitted light radiance from PRE9 was substantially lower than that of luc2, both in vitro and in vivo. We conclude that PRE9 has favorable properties as compared to luc2 in terms of pH independence, red-shifted spectrum, tissue light penetration, and signal quantification, justifying further optimization of protein expression and enzymatic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.